In conversation with... Tasdik Hasan
Mar 19, 202633m0
A Health Policy piece in our April issue by Tasdik Hasan and co-authors titled: Co-designing a Bangla Mental Health Sign Language Bank in Bangladesh
Hosted by The Lancet · EN-UK · 703 episodes
Established thought leaders with verified media credentials.
The Lancet (www.thelancet.com) is a weekly medical journal, renowned for the publication of high-quality peer-reviewed research and reviews from around the world. In the Podcasts our editors discuss journal highlights, including interviews with authors of key articles to provide context and insight to advancements in medicine and health worldwide.
The Lancet hosts Listen to The Lancet, a science show with 703 episodes published.
A Health Policy piece in our April issue by Tasdik Hasan and co-authors titled: Co-designing a Bangla Mental Health Sign Language Bank in Bangladesh
Can personality disorder treatments be reduced to just a few months?
In this episode, co-hosted by our Senior Editor Amy Slogrove and our Lancet Child & Adolescent Health Youth Advisory Panel member, Matea Canizares, we discuss adolescent digital intimate partner violence.
The uniqueness of each patient is at the heart of this year's World Cancer Day. In this Podcast you will hear from two cancer survivors about their unique experience with cancer and the importance of personalised cancer
In Conversation with The Lancet returns with Dr Susannah Stanway, honorary consultant medical oncologist at the Royal Marsden and honorary clinical senior lecturer in Education at the Institute of Cancer Research, reflec
Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025
Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax followed
Ultra-processed foods are on the rise. Despite the emphasis placed on individual responsibility, our deteriorating diets are primarily the result of the sophisticated political tactics of a powerful global ultra-processe
Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 202
Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025.
Walter Willett, Shakuntala Thilsted and Johan Rockström discuss the second EAT-Lancet Commission report.
Stephen Chan joins Ben Abbott of The Lancet to discuss the key messages of the Lancet Commission on addressing the global hepatocellular carcinoma burden, which is published today on World Hepatitis Day.
Rebecca Fitzgerald joins us to discuss her recent prospective real-world implementation study of capsule sponge risk stratification in Barrett’s oesophagus surveillance in the UK.
Changsong Qi joins Chloe Wilson and Ben Abbott of The Lancet to discuss their recently published phase 2 randomised controlled trial investigating Claudin-18 isoform 2-specific CAR T-cell therapy for previously treated a
Francis Couturaud joins Chloe Wilson of The Lancet to discuss the RENOVE trial, which looks at assessing the efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in patients in whom extended an
Donald Trump has taken office in the US and immediately turned his attention to dismantling the US position as a world leader in global health. How will actions taken so far affect the health of people around the world?
Michael Heneka joins Chloe Wilson and Bea Gomez Perez-Nievas of The Lancet to discuss a therapeutics paper discussing the opportunities and challenges of passive anti-amyloid β immunotherapy in Alzheimer's disease.
ROSHNI-2 was a multicentre, randomised controlled trial that investigated the efficacy of a culturally adapted, cognitive behavioural therapy-based intervention for postnatal depression in British south Asian women. Join
Rasha Al-Lamee and Shayna Chotai join Chloe Wilson of The Lancet to discuss ESC Congress 2024 highlights.
Gavin is joined by Paul Moran and Helen Christensen to discuss The Lancet's new commission on self-harm, exploring its prevalence, cultural factors, and the crucial need for better data and compassionate care. We also ta
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Listen to The Lancet has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Listen to The Lancet is hosted by The Lancet. The show is categorised under science (medicine) and has published 703 episodes.
Listen to The Lancet has published 703 episodes.
Listen to The Lancet regularly covers science, medicine, health. It sits in the science category, with a medicine focus.
Listen to The Lancet is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Listen to The Lancet hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Listen to The Lancet average 30 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Listen to The Lancet's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 5 days ago.